Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy. Issue 3 (May 2022)

• Record Type: Journal Article
• Authors: Atkinson, M.; Lansdown, A.J.
• Is Part Of: Best practice & research. Volume 36:Issue 3(2022)
• Publication Date: 2022-05
• Subjects: Immunotherapy -- immune checkpoint inhibitors -- adrenal insufficiency -- diabetes insipidus -- hypoparathyroidism -- lipodystrophy; ICI immune checkpoint inhibitor -- irAE immune-related adverse event -- AI adrenal insufficiency -- PAI primary adrenal insufficiency -- SAI secondary adrenal insufficiency -- ACTH adrenocorticotrophic releasing hormone -- PTH parathyroid hormone -- DI diabetes insipidus; Endocrine glands -- Diseases -- Periodicals; Metabolism -- Disorders -- Periodicals; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1016/j.beem.2022.101635
• Languages: English
• ISSNs: 1521-690X

Abstract

Abstract : Immune checkpoint inhibitors are being prescribed increasingly widely for a range of malignancies. They are effective at treating certain cancers, but also have significant side effects. Evidence suggests that efficacy is greatest in patients who experience one or more immune-related adverse events (irAEs). Common irAEs include skin and hepatic reactions, and a range of immune-related endocrinopathies. These include hypophysitis, thyroid disease, and autoimmune diabetes mellitus, and rarer endocrinopathies such as primary adrenal insufficiency, diabetes insipidus, parathyroid disease, autoimmune polyglandular syndrome, lipodystrophy, and ACTH-dependent Cushing's syndrome. Herein, we review the current literature related to these rarer immunotherapy-induced endocrinopathies.